European Journal of Pediatrics

, Volume 165, Issue 7, pp 476–480 | Cite as

CNS-manifestation of aspergillosis in an extremely low-birth-weight infant

  • Hans Fuchs
  • Heike von Baum
  • Martina Meth
  • Nele Wellinghausen
  • Wolfgang Lindner
  • Helmut Hummler
Original Paper

Abstract

Invasive aspergillosis is a rare condition in term and preterm infants. We present here the fatal case of a 28-week gestational age preterm baby who developed pulmonary, hepatic and central nervous system aspergillosis during the first days of life. A hyperechogenic lesion adjacent to the lateral ventricle was diagnosed by ultrasound and initially considered to represent periventricular leukomalacia. Within several days the lesion increased in size and was then falsely considered to be an intraventricular haemorrhage. Aspergillus fumigatus was ultimately isolated in the tracheal aspirates, ascites and in material recovered by open brain biopsy. Despite treatment with conventional and liposomal amphotericin B the infant patient died. Conclusion. Invasive aspergillosis has to be considered in the differential diagnosis of an unusual hyperechogenic brain lesion in very low-birth-weight infants with persistent symptoms and signs of systemic infection despite broad-spectrum antibacterial therapy. Consideration of this diagnosis should result in an aggressive diagnostic work-up to allow early initiation of an appropriate treatment.

Keywords

Aspergillosis Infant Intraventricular haemorrhage Newborn Periventricular leukomalacia Very low-birth-weight infant 

Abbreviations

CNS

Central nervous system

CSF

Cerebrospinal fluid

CrP

C-reactive protein

ELBW

Extremely low-birth-weight

MRI

Magnetic resonance imaging

sp

species

References

  1. 1.
    Ader F, Nseir S, Le Berre R, Leroy S, Tillie-Leblond I, Marquette CH, Durocher A (2005) Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol Infect 11:427–429CrossRefPubMedGoogle Scholar
  2. 2.
    Ben Rejeb A, Boubaker S, Turki I, Massaoudi L, Chibani M, Khouja H (1993) Placental aspergillosis: myth or reality? Apropos of a case with fetal death in utero. J Gynecol Obstet Biol Reprod 22:85–89Google Scholar
  3. 3.
    Buchheidt D, Hummel M, Schleiermacher D, Spiess B, Hehlmann R (2004) Current molecular diagnostic approaches to systemic infections with aspergillus species in patients with hematological malignancies. Leukemia Lymphoma 45:463–468CrossRefPubMedGoogle Scholar
  4. 4.
    Chiang AK, Chan GC, Ma SK, Ng YK, Ha SY, Lau YL (2000) Disseminated fungal infection associated with myeloperoxidase deficiency in a premature neonate. Pediatr Infect Dis J 19:1027–1029PubMedCrossRefGoogle Scholar
  5. 5.
    Galimberti R, Kowalczuk A, Hidalgo Parra I, Gonzalez Ramos M, Flores V (1998) Cutaneous aspergillosis: a report of six cases. Br J Dermatol 139:522–526CrossRefPubMedGoogle Scholar
  6. 6.
    Groll AH, Jaeger G, Allendorf A, Herrmann G, Schloesser R, von Loewenich V (1998) Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life. Clin Infect Dis 27:437–452PubMedCrossRefGoogle Scholar
  7. 7.
    Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, Piscitelli SC, Walsh TJ (2000) Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 182:274–282CrossRefPubMedGoogle Scholar
  8. 8.
    Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B (2002) Invasive fungal infections group of the European organisation for research and treatment of cancer and the global aspergillus study group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415CrossRefPubMedGoogle Scholar
  9. 9.
    Herron MD, Vanderhooft SL, Byington C, King JD (2003) Aspergillosis in a 24-week newborn: a case report. J Perinatol 23:256–259CrossRefPubMedGoogle Scholar
  10. 10.
    Kontoyiannis DP, Mantadakis E, Samonis G (2003) Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect 53:243–258CrossRefPubMedGoogle Scholar
  11. 11.
    Lin SJ, Schranz J, Teutsch SM (2001) Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32:358–366CrossRefPubMedGoogle Scholar
  12. 12.
    Maertens J, Verhaegen J, Demuynck H, Brock P, Verhoef G, Vandenberghe P, Van Eldere J, Verbist L, Boogaerts M (1999) Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol 37:3223–3228PubMedGoogle Scholar
  13. 13.
    Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M (2002) Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 186:1297–1306CrossRefPubMedGoogle Scholar
  14. 14.
    Marcinkowski M, Bauer K, Stoltenburg-Didinger G, Vogel M, Versmold H (2000) Fatal aspergillosis with brain abscesses in a neonate with DiGeorge syndrome. Pediatr Infect Dis J 19:1214–1216PubMedCrossRefGoogle Scholar
  15. 15.
    Mitchell SJ, Gray J, Morgan ME, Hocking MD, Durbin GM (1996) Nosocomial infection with Rhizopus microsporus in preterm infants: association with wooden tongue depressors. Lancet 17:441–443CrossRefGoogle Scholar
  16. 16.
    Muldrew KM, Maples HD, Stowe CD, Jacobs RF (2005) Intravenous voriconazole therapy in a preterm infant. Pharmacotherapy 25:893–898CrossRefPubMedGoogle Scholar
  17. 17.
    Muller FM, Trusen A, Weig M (2002) Clinical manifestations and diagnosis of invasive aspergillosis in immunocompromised children. Eur J Pediatr 161:563–574CrossRefPubMedGoogle Scholar
  18. 18.
    Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I, Salit I, Miller M, Williams K, Conly JM, Singer J, Ioannou S (1997) Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 16:337–345CrossRefPubMedGoogle Scholar
  19. 19.
    Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL (2005) Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 43:57–62CrossRefPubMedGoogle Scholar
  20. 20.
    Popova NI (1976) Intrauterine destruction of the brain by molds. Ark Patol 38:48–52Google Scholar
  21. 21.
    Richardson V, Ortiz D, Newton OA, Nandi E (2001) Disseminated and cutaneous aspergillosis in a premature infant: a fatal nosocomial infection. Pediatr Dermatol 18:366–367CrossRefPubMedGoogle Scholar
  22. 22.
    Schwartz DA, Jacquette M, Chawla HS (1988) Disseminated neonatal aspergillosis: report of a fatal case and analysis of risk factors. Pediatr Infect Dis J 7:349–353PubMedCrossRefGoogle Scholar
  23. 23.
    Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, Schuler U, Lutsar I, Troke P, Thiel E (2005) Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106:2641–2645CrossRefPubMedGoogle Scholar
  24. 24.
    Siemann M, Koch-Dorfler M, Gaude M (1998) False-positive results in premature infants with the Platelia Aspergillus sandwich enzyme-linked immunosorbent assay. Mycoses 41:373–377PubMedCrossRefGoogle Scholar
  25. 25.
    Singer S, Singer D, Ruchel R, Mergeryan H, Schmidt U, Harms K (1998) Outbreak of systemic aspergillosis in a neonatal intensive care unit. Mycoses 41:223–227PubMedGoogle Scholar
  26. 26.
    Steinbach WJ (2005) Pediatric aspergillosis: disease and treatment differences in children. Pediatr Infect Dis J 24:358–364CrossRefPubMedGoogle Scholar
  27. 27.
    Strunk T, Temming P, Gembruch U, Reiss I, Bucsky P, Schultz C (2004) Differential maturation of the innate immune response in human fetuses. Pediatr Res 56:219–226CrossRefPubMedGoogle Scholar
  28. 28.
    Vermes A, Guchelaar HJ, Dankert J (2000) Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 46:171–179CrossRefPubMedGoogle Scholar
  29. 29.
    Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ (1998) Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26:1383–1396PubMedCrossRefGoogle Scholar
  30. 30.
    Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR (2002) Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 21:240–248CrossRefPubMedGoogle Scholar
  31. 31.
    Woodruff CA, Hebert AA (2002) Neonatal primary cutaneous aspergillosis: case report and review of the literature. Pediatr Dermatol 19:439–444CrossRefPubMedGoogle Scholar
  32. 32.
    Zaoutis TE, Foraker E, McGowan KL, Mortensen J, Campos J, Walsh TJ, Klein JD (2005) Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children’s hospitals. Diagn Microbiol Infect Dis 52:295–298CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Hans Fuchs
    • 1
  • Heike von Baum
    • 2
  • Martina Meth
    • 3
  • Nele Wellinghausen
    • 4
  • Wolfgang Lindner
    • 1
  • Helmut Hummler
    • 1
  1. 1.Division of Neonatology and Pediatric Critical Care, Department of PediatricsChildren’s Hospital, University of UlmUlmGermany
  2. 2.Department of Medical Microbiology and HygieneUniversity of UlmUlmGermany
  3. 3.Department of PathologyUniversity of UlmUlmGermany
  4. 4.Department of Medical Microbiology and HygieneUniversity of UlmUlmGermany

Personalised recommendations